Results 41 to 50 of about 10,027 (205)

Inactive Graves’ orbitopathy: to treat or not to treat?

Российский офтальмологический журнал, 2023
Purpose: to evaluate the expediency and efficacy of conservative therapy of patients with inactive stages of Graves’ orbitopathy complicated by optical neuropathy. Materials and methods.
O. G. Panteleeva, F. H. Batyrbekova
doaj   +1 more source

Diagnosis of Graves’ Orbitopathy

, 2023
Abstract The diagnosis of Graves’ orbitopathy is based on a typical clinical presentation, supported by a family history of Graves’ disease, in combination with typical findings on CT or MRI scans and/or elevated serum levels of TSH-receptor-binding immunoglobulins and anti-thyroid peroxidase.
openaire   +2 more sources

The Tutopatch® assisted surgery for complex strabismus study: TASCS‐study

Acta Ophthalmologica, Volume 104, Issue 7, Page 818-827, November 2026.
Abstract Purpose To investigate the efficacy of tendon elongation using bovine pericardium (Tutopatch®) in complex strabismus surgeries, with a specific focus on longer follow‐up of postoperative outcomes and patient satisfaction. Methods In this pre‐post cohort study, the records of all patients who underwent tendon elongation strabismus surgery with ...
Ires A. W. Verhees, Hinke Marijke Jellema, Anne‐Marie E. L. Langenhorst, B. Jeroen Klevering, Laurentius J. van Rijn, Annabel L. W. Groot   +5 more
wiley   +1 more source

Evaluation of Intraocular Pressure in Thyroid-associated Orbitopathy

Journal of Nepal Health Research Council, 2022
Background: Elevated intraocular pressure in thyroid associated orbitopathy may lead to development of secondary glaucoma in them. This study evaluated IOP in primary gaze correlation with clinical activity score in them.
Pragati Gautam Adhikari, Gulshan Bahadur Shrestha   +1 more
doaj   +1 more source

Periorbital Fat Loss From Prostaglandin Analogues: Dermatologic and Cosmetic Considerations

Journal of Cosmetic Dermatology, Volume 25, Issue 11, November 2026.
ABSTRACT Background Topical prostaglandin (PG) analogues, originally developed as first‐line therapies for glaucoma, are increasingly used in dermatology and cosmetic settings to promote eyelash and eyebrow growth. However, their use has been associated with prostaglandin‐associated periorbitopathy (PAP), a constellation of adverse effects including ...
Lily Kaufman, Aliza Khuhro, Sierra Schwierking, Lilia Valentic, Sonja Kobayashi, Lauren Malley, Olivia Ueltschi, Lucy Rose, Brittany Dulmage   +8 more
wiley   +1 more source

Thyroid Orbitopathy and Dry Eye

, 2011
Thyroid orbitopathy (TO) is an inflammatory autoimmune disease of the orbital and periorbital tissues that is characterized by the presence of autoantibodies against thyroid-stimulating hormone receptor (TSH-R).
Canan Gürdal, Özge Saraç
core   +1 more source

A Tear Metabolomic Profile Showing Increased Ornithine Decarboxylase Activity and Spermine Synthesis in Thyroid-Associated Orbitopathy [PDF]

, 2022
About half of patients with Graves’ disease develop an orbitopathy related to an inflammatory expansion of the periorbital adipose tissue and muscles. We used a targeted metabolomic approach measuring 188 metabolites by mass spectrometry to compare
Gohier, Philippe, Juan Manuel Chao de la Barca, Geoffrey Urbanski, Assad, Sophie, Ferré, Marc, Billiet, Benjamin, Jeanne Muller, Philippe Gohier, Marc Ferré, Gilles Simard, Pascal Reynier, Urbanski, Geoffrey, Anaïs Vautier, Muller, Jeanne, Simard, Gilles, Tessier, Lydie, Céline Wetterwald, Benjamin Billiet, Faure, Justine, Vautier, Anaïs, Odile Blanchet, Blanchet, Odile, de la Barca, Juan Manuel Chao, Sophie Assad, Delphine Mirebeau-Prunier, Wetterwald, Céline, Mirebeau-Prunier, Delphine, Patrice Rodien, Reynier, Pascal, Rodien, Patrice, Justine Faure, Lydie Tessier   +31 more
core   +1 more source

Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves’ disease

Archives of Endocrinology and Metabolism, 2017
Objective The aim of this study was to measure quality of life (QOL) impairment in individuals currently suffering from Graves’ ophthalmopathy (GO) and to determine the correlation of GO-specific QOL scores with disease severity and activity.
Laura Carolina Delfino, Anabela Zunino, Verónica Sapia, María del Carmen Silva Croome, Verónica Ilera, Alicia Teresa Gauna   +5 more
doaj   +1 more source

The Amsterdam Declaration on Graves' Orbitopathy [PDF]

Thyroid, 2010
For decades, clinicians who manage patients with Graves’ orbitopathy (GO) have been anticipating the emergence of new effective therapies for the management of this condition. That dream has yet to come true, but it has become apparent that conventional treatments such as steroids and surgery, when applied at the appropriate time and by centres that ...
Perros, P., Wiersinga, W.M.
openaire   +4 more sources

IgG4‐Related Disease Overlapping With Anti‐Acetylcholine Receptor Antibody–Positive Myasthenia Gravis

Clinical and Experimental Neuroimmunology, Volume 17, Issue 3, August 2026.
ABSTRACT Background IgG4‐related disease (IgG4‐RD) is a systemic, immune‐mediated, fibroinflammatory disorder with multiorgan involvement and variable clinical presentation, often creating diagnostic difficulty. Myasthenia gravis (MG) is an antibody‐mediated autoimmune disorder of the neuromuscular junction, most commonly associated with anti ...
Yumiko Yoshida, Ayami Okuzumi, Yuka Hosaka, Yuji Tomizawa, Taku Hatano   +4 more
wiley   +1 more source